Abstract Number: 0332 • ACR Convergence 2024
Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…Abstract Number: 0687 • ACR Convergence 2024
Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease
Background/Purpose: Understanding the trajectory of disease progression in SSc-ILD is crucial for effective patient management and prognostication. Trajectory modeling offers a novel approach to deciphering…Abstract Number: 0950 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the most overrepresented cause of death among RA patients, yet the mechanisms underlying lung fibrosis remain…Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…Abstract Number: 1689 • ACR Convergence 2024
Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Background/Purpose: Black individuals with systemic sclerosis (SSc) have an increased frequency and severity of interstitial lung disease (ILD) as compared to their White counterparts. Pulmonary…Abstract Number: 2075 • ACR Convergence 2024
A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)
Background/Purpose: ILD is associated with poor survival in patients with idiopathic inflammatory myopathies (IIM). Cyclophosphamide is often used in the management of myositis associated ILD…Abstract Number: 2466 • ACR Convergence 2024
Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in…Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…Abstract Number: 0690 • ACR Convergence 2024
Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database
Background/Purpose: Inflammation and vasculopathy may play a role in the development of interstitial lung disease (ILD) in systemic sclerosis (SSc). Pre-clinical evidence showed possible preventive…Abstract Number: 0952 • ACR Convergence 2024
Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…Abstract Number: 1690 • ACR Convergence 2024
FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study
Background/Purpose: 68Ga-FAPI-PET/CT is a novel imaging method monitoring in-vivo fibroblast activation. We recently described an association of 68Ga-FAPI-uptake with deterioration of Forced Vital capacity (FVC)…Abstract Number: 2084 • ACR Convergence 2024
Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study
Background/Purpose: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints,…Abstract Number: 2470 • ACR Convergence 2024
Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
Background/Purpose: The occurrence of interstitial lung disease (ILD) in the course of systemic sclerosis (SSc) is associated with increased morbidity and mortality. SSc-ILD evolution is…Abstract Number: 0338 • ACR Convergence 2024
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…
- 1
- 2
- 3
- …
- 39
- Next Page »